Oncolytics Biotech (ONCY) Depreciation & Amortization (CF) (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Depreciation & Amortization (CF) of $69791.0 for Q4 2025, up 39.28% year-over-year from $50109.4 in Q4 2024, and up 139098.33% quarter-over-quarter from $50.14 in Q3 2025.
Oncolytics Biotech (ONCY) Depreciation & Amortization (CF) (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $69791.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 39.28% year-over-year to $69791.0; the TTM figure through Dec 2025 stood at $169120.4 (down 1.58% YoY), while the FY2025 annual figure was $70000.0, down 68.47% from the prior year.
- Depreciation & Amortization (CF) rose to $69791.0 in Q4 2025 per ONCY's latest filing, from $50.14 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $71991.5 in Q2 2021 and bottomed at $50.14 in Q3 2025.
- Historically, Depreciation & Amortization (CF) has averaged $53325.0 across 5 years, with a median of $57374.5 in 2022.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) sank 99.92% — and 2025, when it soared 39.28%.
- Oncolytics Biotech's Depreciation & Amortization (CF) stood at $58618.8 in 2021, then slipped by 3.23% to $56726.1 in 2022, then gained by 13.95% to $64639.1 in 2023, then fell by 22.48% to $50109.4 in 2024, then jumped by 39.28% to $69791.0 in 2025.
- Business Quant data shows ONCY's Depreciation & Amortization (CF) at $69791.0 in Q4 2025, $50.14 in Q3 2025, and $49798.2 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 69,791.00 |
| Dec 31, 2025 | 69,791.00 |
| Sep 30, 2025 | 50.14 |
| Sep 30, 2025 | 50.14 |
| Jun 30, 2025 | 49,798.16 |
| Jun 30, 2025 | 49,798.16 |
| Mar 31, 2025 | 49,481.07 |
| Mar 31, 2025 | 49,481.07 |
| Dec 31, 2024 | 50,109.44 |
| Dec 31, 2024 | 50,109.44 |
| Sep 30, 2024 | 50.58 |
| Sep 30, 2024 | 50.58 |
| Jun 30, 2024 | 51,179.84 |
| Jun 30, 2024 | 51,179.84 |
| Mar 31, 2024 | 70,500.75 |
| Mar 31, 2024 | 70,500.75 |
| Dec 31, 2023 | 64,639.13 |
| Dec 31, 2023 | 64,639.13 |
| Sep 30, 2023 | 61,912.23 |
| Sep 30, 2023 | 61,912.23 |